Cartesian Therapeutics, Inc.

NasdaqGM:RNAC Stock Report

Market Cap: US$430.5m

Cartesian Therapeutics Management

Management criteria checks 1/4

Cartesian Therapeutics' CEO is Carsten Brunn, appointed in Dec 2018, has a tenure of 5.92 years. total yearly compensation is $6.11M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $147.89K. The average tenure of the management team and the board of directors is 1 years and 5 years respectively.

Key information

Carsten Brunn

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage10.1%
CEO tenure5.9yrs
CEO ownership0.03%
Management average tenureless than a year
Board average tenure5yrs

Recent management updates

Recent updates

Cartesian Therapeutics: Uncertainty Remains

Nov 10

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 17

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 02

CEO Compensation Analysis

How has Carsten Brunn's remuneration changed compared to Cartesian Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$282m

Jun 30 2024n/an/a

-US$267m

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$618k

-US$257m

Compensation vs Market: Carsten's total compensation ($USD6.11M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Insufficient data to compare Carsten's compensation with company performance.


CEO

Carsten Brunn (53 yo)

5.9yrs

Tenure

US$6,111,883

Compensation

Dr. Carsten Brunn, Ph.D. serves as President, Chief Executive Officer & Director of Cartesian Therapeutics, Inc. since December 2018. He served as an Independent Director at Surface Oncology, Inc. since Ju...


Leadership Team

NamePositionTenureCompensationOwnership
Carsten Brunn
President5.9yrsUS$6.11m0.034%
$ 147.9k
Blaine Davis
Chief Financial Officer2yrsUS$2.49mno data
Metin Kurtoglu
Chief Technology Officerless than a yearUS$398.28k0%
$ 0
Chris Jewell
Chief Scientific Officerless than a yearUS$296.85k0%
$ 0
Matthew Bartholomae
General Counsel & Secretaryno datano datano data
Milos Miljkovic
Chief Medical Officerless than a yearno data0%
$ 0
Emily English
SVP & Head of Manufacturingless than a yearno data0%
$ 0

1.0yrs

Average Tenure

44.5yo

Average Age

Experienced Management: RNAC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Carsten Brunn
President5.9yrsUS$6.11m0.034%
$ 147.9k
Carrie Cox
Independent Chairman of the Board5yrsUS$292.32k0.028%
$ 120.2k
Timothy Barabe
Independent Director8.3yrsUS$212.93k0.062%
$ 268.2k
Patrick Zenner
Independent Director7.4yrsUS$192.05k0.0072%
$ 31.2k
Timothy Springer
Director8.4yrsUS$192.73k34.93%
$ 150.4m
Nishan DeSilva
Independent Director3.4yrsUS$188.58k0.00092%
$ 4.0k
Kemal Malik
Independent Directorless than a yearno data0%
$ 0
Murat Kalayoglu
Independent Directorless than a yearUS$5.37k19.89%
$ 85.6m
Michael Singer
Independent Directorless than a yearUS$5.71k1.21%
$ 5.2m

5.0yrs

Average Tenure

62yo

Average Age

Experienced Board: RNAC's board of directors are considered experienced (5 years average tenure).